Navigation Links
Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
Date:1/26/2009

TAMPA, Fla., Jan. 26 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that its New Drug Application (NDA) for ganciclovir ophthalmic gel, 0.15%, has been accepted for review by the U.S. Food and Drug Administration (FDA). Sirion Therapeutics is seeking approval for ganciclovir as a treatment for herpetic keratitis, an ocular disease caused by the herpes simplex virus. The FDA has issued an action date in late fall of 2009, under the Prescription Drug User Fee Act.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

"Herpes simplex keratitis remains one of the leading causes of corneal blindness and corneal transplants in the United States," explained Barry Butler, CEO of Sirion Therapeutics. "If approved by the FDA, ganciclovir ophthalmic gel would become the first topical ophthalmic antiviral treatment launched in the U.S. in almost three decades. This product would provide a significant new option for physicians in the treatment of patients with herpetic keratitis."

To assess the efficacy and safety of ganciclovir, four randomized, multicenter trials compared ganciclovir gel, 0.15%, with acyclovir ointment, 3%, both of which are used as first-line therapies outside the U.S. to treat herpetic keratitis. The studies found that ganciclovir is as effective as acyclovir and that the tolerability of ganciclovir was superior to acyclovir, particularly with regard to blurring and stinging or burning sensations after instillation. Additionally, since ganciclovir is formulated as an aqueous gel, it allows for prolonged contact time with the corneal surface.

"Based upon its proven safety and efficacy, the introduction of a new topical antiviral agent with improved tolerability, such as ganciclovir ophthalmic gel, would clearly be a
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
2. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
5. Sirion Therapeutics Supports Ophthalmic Education
6. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
7. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
8. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
9. Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program
10. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
11. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Marktech Optoelectronics is pleased to introduce a new ... internal gain mechanism, fast time response, low dark current ... APD’s are recommended for applications that require high bandwidth, ... pre-amp noise. In addition, Marktech APD's provide higher sensitivity ... low-level light detection and short pulse detection. , ...
(Date:6/3/2015)... June 03, 2015 From smart street ... important part in enabling success in dealing with important ... technology leaders helped bring focus to the role and ... Photonics21 annual meeting last week in Brussels. ... event, held 28 and 29 May at the Hotel ...
(Date:6/2/2015)... MIAMI (PRWEB) June 02, 2015 Global ... Latin America distributor for Bioquark, Inc.’s biologic products for the ... is the latest in Global Stem Cells Group’s ambitious expansion ... region’s growing demand for access to regenerative medicine and stem ... on the development of biologics that have the ability to ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
Breaking Biology Technology:Marktech Introduces New Line of APDs 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3
... Novo Nordisk, a,healthcare company with an 84-year history ... the appointment of Alan C. Moses, M.D. as,vice ... the,chief medical officer of Novo Nordisk Inc., the ... talent to integrate the science of discovery with,new ...
... Dx Breast Cancer Profile Represents First Molecular ... Stages of Operable Breast Cancer, ALISO VIEJO, Calif., ... premier technology and services resource for,pathologists, oncologists and the ... breast cancer test, the first molecular,test available that is ...
... Banking acted as,exclusive financial advisor to NPS Pharmaceuticals ... the terms of the agreement, NPS has licensed ... the treatment of gastrointestinal disorders., Gattex is ... of,short-bowel syndrome (SBS). SBS can result from one ...
Cached Biology Technology:Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide 2Clarient to Commercialize Novel Breast Cancer Profile 2Clarient to Commercialize Novel Breast Cancer Profile 3Clarient to Commercialize Novel Breast Cancer Profile 4Clarient to Commercialize Novel Breast Cancer Profile 5Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement 2
(Date:5/28/2015)... , May 28, 2015 Industry ... of a new report titled "Markets for Self-Healing ... polymers, inorganic capsule and vascular systems, biomaterials, relevant ... grow to around $2.7 billion by 2020. ... n-tech,s extensive coverage of smart materials. Other recent n-tech ...
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... resistance in bacteria may also be involved in exporting ... quorum sensing, said researchers from Baylor College of Medicine ... Proceedings of the National Academy of Sciences. , "We ... actually be similar in structure to molecules involved in ...
... bugs targeted by vaccines recently announced by the Department ... scientists from the Wellcome Trust Sanger Institute. They have ... the vaccine that will help monitor the disease and ... name Streptococcus pneumoniae) are widespread, causing non-invasive disease, such ...
... a key component of the mechanism spermatozoa use to ... undulation to the whip-cracking snap that thrusts them into ... that the researchers said could help scientists both recognize ... to thwart sperm entry into the egg. , What's ...
Cached Biology News:Drug resistance may travel same path as quorum sensing 2Outsmarting the smartie bug 2Outsmarting the smartie bug 3How sperm crack the whip 2How sperm crack the whip 3
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
...
Human PDGF, CF...
... The mycobacteria in Complete Freund's adjuvant attract ... site which enhances the immuneresponse. For this ... for the initial injections; Incomplete Freund's adjuvant ... (preferably in saline) are typically mixed with ...
Biology Products: